Highlights 2017 2017 2016 6 Reported growth Growth at constant currency 1 Group revenue (£ million) 96.9 83.2 16% 12% Adjusted 2 operating margin (%) 26.2 23.7 250bps – Adjusted 2 profit before tax (£ million) 25.4 19.7 29% – Profit before tax (£ Financial e Good revenue growth, up 16% to £96.9 million and by 12% at constant currency • Branded revenues up 22% to £55.2 million (2016: £45.4 million), and by 16% at constant currency • OEM revenues up 10% to £41.7 million (2016: £37.8 million 02 Advanced Medical Solutions Group plc Annual Report 2017 £96.9m Global sales £25.4m Adjusted 2 profit before tax 1 Advanced woundcare market includes alginates, gelling fibre dressings, contact layers, hydrocolloids, hydrogels, superabsorbents, silver AMS continues to progress as a leading international provider of high quality, high value, innovative and technologically advanced products for the surgical and advanced wound care markets.We are pleased to report another year of strong revenue growth, profit performance and cash generation.Our revenues increased 16% to £96.9 million (2016: £83.2 million Revenue from our RESORBA ® brands grew steadily across all territories and has grown by 15% and by 6% at constant currency to £20.8 million (2016: £18.1 million), while ActivHeal ® grew by 4% to £6.3 million (2016: £6.0 million).Peter Allen Chairman Revenue +16% +12% * to £96.9m (2016: £83.2m) * at constant currency Adjusted 1 profit before tax +29% to £25.4m (2016: £19.7m) Advanced Medical Solutions Group plc Annual Report 2017 04 Creating quality outcomes for our employees, customers and for patients Chief Executive's Statement We access this market through distributors who target both hospitals and non hospitals, helping us to identify customers and convert opportunities into sales following surgeon evaluation.We support our partners with marketing and clinical data demonstrating the efficacy of our products.We continue to grow our volume market share which is now at 26%, up this accurate laparoscopic application of adhesive is expected to both reduce surgical complications and reduce the potential pain associated with the use of tacks and staples.it also provides the ability to attach mesh in areas where tacks and staples cannot be applied, helping to improve the patient experience and surgical outcomes within this, sales of sutures increased by 15% to £13.0 million (2016: £11.3 million) and by 6% at constant currency and sales of bio surgical products increased by 16% to £7.9 million (2016: £6.8 million) and by 8% at constant currency.we have been working with many of the world's major wound care companies for a number of years providing manufacturing services to supply their woundcare dressings, new products they can incorporate into their portfolio of brands, as well as regulatory assistance in obtaining product approvals in overseas markets.Revenue increased 10% to £41.7 million (2016: £37.8 million Organogenesis has been granted an exclusive license in the United States to the patent.In exchange for this, we have recognised £2.5 million from royalties, and will receive a minimum royalty of $1 million for each of the financial years ending 31 December 2018 and 2019.This is part of an ongoing royalty stream that will be payable to AMS on the net We were very pleased with the outcome of this audit with no non conformances raised.The new European Medical Devices Regulation (MDR) entered into force on 25 May 2017, marking the start of the transition period for manufacturers selling medical devices into Europe.The MDR, which replaces the Medical Devices Directive (MDD) has a transition period of three years our culture As a Group that is highly dependent on the innovation and creativity of our employees for our future growth and success, it is important that we have a culture and set of values that is understood and embraced across the business.We have adopted the business motto of 'The AMS Care, Fair, Dare approach' A continuing trend towards minimally invasive surgery further provides opportunities for innovations and market growth.Healthcare economics demand cost effective product solutions.AMS's mission is to meet these needs.Healthcare economics demand cost effective product solutions.AMS's mission is to meet these needs.Revenue £55.2m Revenue £41.7 m Third party products Own brand products Advanced Medical Solutions Group plc Annual Report 2017 Company Overview Strategic Report Governance Financial Statements 11 Our Business Units Creating quality outcomes through our innovative products The Branded Business Unit is focused on driving sales, innovation and distribution for our brands globally.LiquiBand ® e Increase usage in the Operating Room (OR) in the UK and Germany through our existing sales teams e Increase the market share of LiquiBand ® in the US by: • Partnering with key distributors that access the US healthcare market • Develop and launch new products • T rain partner personnel, and provide marketing Strategy Advanced Medical Solutions Group plc Annual Report 2017 Company Overview Strategic Report Governance Financial Statements 13 Our Business Units continued LiquiBand ® The LiquiBand ® range of products has been developed to provide innovative solutions to close wounds and minimise adverse surgical outcomes.Our products have been uniquely designed to meet the needs of clinicians and patients for safe, The applicators also incorporate different tip designs such as a foam dome to provide broad application or a thin cannula shaped tip to provide controlled and precise adhesive placement in a more enclosed application.We also sell LiquiBand ® into the OR in the UK and Germany where it is used to make the final topical skin closure following the surgical procedure 14 LiquiBand ® Fix8TM Our LiquiBand ® Fix8TM device is a safe and effective device that secures implantable mesh to underlying tissues for laparoscopic hernia repair.LiquiBand ® Fix 8TM is easy to use and allows precise and controlled in Laparoscopic intraperitoneal onlay mesh repair (IPOM) Incisional hernia repair, it has allowed me to extend the range of meshes used – allowing excellent fixation of biologic mesh in complex patients, as well as synthetic mesh fixation.LiquiBand ® Fix8TM the total US surgical suture market is estimated to be in excess of $1 billion in size and is dominated by a few major brands.During 2016 we renegotiated an OEM supply agreement for collagen products in global territories, including RESODURA ® and GENTA COLL ®.AMS welcomed the opportunity to showcase our products and speak with and understand the challenges clinicians face at the forefront of woundcare.